From Undruggable to Indispensable:Orphan GPCRs in CNS Disease

Once overlooked for lacking ligands, several orphan GPCRs are now under active investigation as disease-modifying targets in Alzheimer’s, Parkinson’s, Huntington’s, and multiple sclerosis (MS). Cryo-EM structures and knockout phenotypes have shifted the narrative from transcriptomic curiosity to therapeutic relevance.

In this blog, we highlight four key receptors — GPR17, GPR37, GPR52, and GPR88 — and the antibodies available to study them.

Anti-GPR17 Antibody (#AGR-048)

Anti-GPR37 (extracellular) Antibody (#AGR-049)

Anti-GPR52 Antibody (#AGR-058)

Anti-GPR88 Antibody (#AGR-038)

These receptors are emerging as promising targets for modulating glial activity, dopaminergic tone, and myelin repair – paving the way for novel insights into CNS health and disease.

Discover more https://www.alomone.com/orphan-gpcrs-re-emerge-as-cns-targets

Per info Contattaci